CorVel Corp. (NASDAQ:CRVL – Get Free Report) insider Maxim Shishin sold 2,250 shares of the stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $60.59, for a total value of $136,327.50. Following the completion of the transaction, the insider directly owned 7,050 shares in the company, valued at approximately $427,159.50. This represents a 24.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
CorVel Trading Down 2.4%
CRVL stock traded down $1.45 during trading on Monday, reaching $58.89. The stock had a trading volume of 197,886 shares, compared to its average volume of 222,599. The stock’s 50 day moving average is $58.08 and its two-hundred day moving average is $60.06. CorVel Corp. has a 52 week low of $44.83 and a 52 week high of $105.69. The firm has a market cap of $2.99 billion, a PE ratio of 27.52 and a beta of 0.99.
CorVel (NASDAQ:CRVL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 19th. The business services provider reported $0.61 EPS for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.51%.The firm had revenue of $248.55 million for the quarter.
Hedge Funds Weigh In On CorVel
Wall Street Analyst Weigh In
CRVL has been the subject of several research analyst reports. Wall Street Zen upgraded CorVel from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. Weiss Ratings downgraded CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CorVel currently has an average rating of “Sell”.
Check Out Our Latest Report on CRVL
About CorVel
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
See Also
- Five stocks we like better than CorVel
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
